International Journal of Medical Science and Pharmaceutical Research

A rapidly increasing demand for cell and gene therapies, despite a stagnant increase in global manufacturing capacity, poses unprecedented challenges to the raw material sourcing and supply chain (RMSS) community. This article discusses the structural weaknesses of the RMSS of cell and gene therapies. These include limited capacity to produce viral vectors and plasmids, geographic concentration of the few specialist suppliers producing those raw materials, and patient-specific production in autologous therapies. Conventional approaches to supplier qualification may be insufficient for these high-risk biological materials, requiring a fundamentally different model for quality assurance. Potential approaches include deep dive technical assessments of prequalified suppliers, dual sourcing, and risk-based tiering of biological materials. Proactive supply chain risk management in clinical development involves the early consideration of the supply chain, planned instead of transactional partnership, geographic technology transfer capabilities, QMSs to manage supplier performance, advanced change control capabilities to account for biological variation, and rapid deviation management to shorten lead times. Regulatory agencies are increasingly requiring proof of supply chain resilience through documented risk management assessments that include justifications for sourcing decisions and contingency plans that are frequently used and exercised. Those organizations that recognize supplier quality management as a planned imperative and invest in dual-sourcing of critical raw materials, strong supply chains, and collaborative relationships with suppliers will deliver transformative therapies. In contrast, those relying on customary supplier practices risk supply failures and limiting patient access to breakthrough therapies.

Cell And Gene Therapy Supply Chain, Viral Vector Manufacturing Capacity, Supplier Qualification Strategies, Risk-Based Quality Management, Dual Sourcing Resilience

1. Umesh Yadav, "Cell and Gene Therapy Market Size, Growth Trends and Forecast to 2025-2033," DataM Intelligence, 2025. Available: https://www.datamintelligence.com/research-report/cell-and-gene-therapy-market
2. Raj Joshi, "Supply chain sourcing and sustainability strategies for cell therapy and advanced biomaterial products," Cell and Gene Therapy Insights, 2024. Available: https://www.researchgate.net/publication/398748195_Supply_chain_sourcing_and_sustainability_strategies_for_cell_therapy_and_advanced_biomaterial_products
3. Fact.MR, "Viral Vector Production (Research-use) Market," 2025. Available: https://www.factmr.com/report/viral-vector-production-research-use-market
4. Demissie Alemayehu et al., "A data-driven approach to quality risk management," Perspect Clin Res., 2013. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC3835966/
5. Pharma Source Global, "Strategic Dual Sourcing: Risk Mitigation Without Complexity," Available: https://pharmasource.global/content/expert-insight/strategic-dual-sourcing-risk-mitigation-without-complexity/
6. Clinical Research News, "Practical Considerations for Managing Cell and Gene Therapy Supply Chains," 2023.  Available: https://www.clinicalresearchnewsonline.com/news/2024/01/05/practical-considerations-for-managing-cell-and-gene-therapy-supply-chains
7. U.S. Food and Drug Administration, "Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)," 2020. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug
8. National Center for Biotechnology Information, "Building Resilience into the Nation's Medical Product Supply Chains," Hardcopy Version at National Academies Press. Available: https://www.ncbi.nlm.nih.gov/books/NBK583751/
9. Patrick Killela et al., National Center for Biotechnology Information, "Mitigation of supply chain challenges in cell therapy manufacturing: perspectives from the cord blood alliance," Stem Cells Transl Med., 2024. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC11386209/
10. Junnan Shi et al., "The clinical quality management system of advanced therapy medicinal products in the hospital setting: A scoping review," Molecular Therapy Methods & Clinical Development, 2025. Available: https://www.sciencedirect.com/science/article/pii/S2329050125000804